Insights into the Pathophysiology of Hypertrophic Scars and Keloids: How Do They Differ?

Adv Skin Wound Care

Feras M. Ghazawi, MD, PhD, MSc • Resident Physician • Division of Dermatology • University of Ottawa • Ottawa, Ontario, Canada • Faculty of Medicine • McGill University • Montreal, Quebec, Canada Ramin Zargham, MD, PhD • Selective Surgical Pathology Fellow • Roswell Park Cancer Institute • Buffalo, New York Mirko S. Gilardino, MD, MSc • Plastic Surgeon • Division of Plastic and Reconstructive Surgery • McGill University Health Centre • Montreal, Quebec, Canada Denis Sasseville, MD • Dermatologist • Division of Dermatology • McGill University Health Centre • Montreal, Quebec, Canada Fatemeh Jafarian, MD • Dermatologist • Division of Dermatology • McGill University Health Centre • Montreal, Quebec, Canada.

Published: January 2018

General Purpose: To provide information about the clinical presentation of hypertrophic scars and keloids based on their varied structural components.

Target Audience: This continuing education activity is intended for physicians, physician assistants, nurse practitioners, and nurses with an interest in skin and wound care.

Learning Objectives/outcomes: After completing this continuing education activity, you should be able to: ABSTRACT: Hypertrophic scars and keloids are firm, raised, erythematous plaques or nodules that manifest when the cicatrix fails to properly heal. They result from pathologic wound healing and often cause pain and decreased quality of life. The appearance of such cosmetically unappealing scars affects the confidence and self-esteem of many patients. These scars can also cause dysfunction by interfering with flexion and extension across joints. Both possess some unique and distinct histochemical and physiologic characteristics that set them apart morphologically and at the molecular level. While these entities have been the focus of research for many years, differentiating between them remains challenging for clinicians.This article reviews the clinical presentation of aberrant scars and illustrates how they can be differentiated. It outlines their pathophysiology and emphasizes the unique molecular mechanisms underlying each disorder. It also examines how altered expression levels and the distribution of several factors may contribute to their unique clinical characteristics and presentation. Further research is needed to elucidate optimal treatments and preventive measures for these types of aberrant scarring.

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.ASW.0000527576.27489.0fDOI Listing

Publication Analysis

Top Keywords

hypertrophic scars
12
scars keloids
12
clinical presentation
8
continuing education
8
education activity
8
scars
6
insights pathophysiology
4
pathophysiology hypertrophic
4
keloids differ?
4
differ? general
4

Similar Publications

Hypertrophic scars (HTSs) are the result of an abnormal healing process resulting from burns and other severe traumas. The symptoms of that condition include skin irritation, discomfort, and itching. This study aimed to assess the efficacy of fractional carbon dioxide (CO) laser therapy alone or with triamcinolone or 5-fluorouracil (FU) in the treatment of early post-burn hypertrophic scars (HTSs) that develop during the first 6 months after the injury.

View Article and Find Full Text PDF

Objective: Determine objectively noticeable features of pediatric facial scars using eye-tracking software and explore how skin tone impacts scar perception.

Study Design: Cross-sectional analysis.

Setting: Tertiary care pediatric hospital.

View Article and Find Full Text PDF

Breast cancer (BC) is a prevalent malignancy in women, often necessitating tumor resection and breast reconstruction surgeries. However, the post-operation scars can be of concern, as hypertrophic scars (HS) can profoundly impact patients' quality of life. Our study used the bidirectional Mendelian randomization (MR) method to explore the potential relationship between BC and HS.

View Article and Find Full Text PDF

Bacterial colonisation in hypertrophic scars (HSs) has been reported, yet the precise mechanism of their contribution to scar formation remains elusive. To address this, we examined HS and normal skin (NS) tissues through Gram staining and immunofluorescence. We co-cultured fibroblasts with heat-inactivated Staphylococcus aureus (S.

View Article and Find Full Text PDF

Microneedle drug delivery system based on hyaluronic acid for improving therapeutic efficiency of hypertrophic scars.

Int J Biol Macromol

January 2025

School of Pharmacy, Xiamen Medical College, Xiamen 361023, PR China; School of Pharmacy, Fujian Medical University, Fuzhou 350108, PR China; Research Center for Sustained and Controlled Release Formulations, Xiamen Medical College, Xiamen 361023, PR China; Key Laboratory of Functional and Clinical Translational Medicine, Fujian Province University, Xiamen Medical College, Xiamen 361023, PR China. Electronic address:

Hypertrophic scar (HS) is a disease with excessive skin fibrosis and collagen disorder, which is generally caused by abnormal wound repair process after burn and trauma. Although intralesional injection of 5-fluorouracil (5-Fu) has been used in clinical treatment of HS, the patients' compliance of injection treatment is poor. In this study, a double-layer dissolution microneedle (MN) containing asiaticoside (AS) and 5-Fu was designed for the treatment of HS.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!